• Title/Summary/Keyword: 흑색종

Search Result 351, Processing Time 0.029 seconds

Analysis of Treatment and Prognosis in Malignant Melanoma (악성 흑색종의 치료와 예후에 대한 분석)

  • Kwon, Young-Ho;Kim, Jeong-Ryoul;Lee, Young-Gu;Kim, Jae-Do
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.11 no.2
    • /
    • pp.141-147
    • /
    • 2005
  • Purpose: The most important thing in curing Malignant melanoma is surgical excision, operating method is wide excision. The author et al. studied 5-year survival rate of each stage and appropriate surgical margin after operating wide excision and immuno-chemotherapy. Materials and methods: From March 1995 to August 2003, wide excision and immunochemotherapy were operated to 35 patients (17 males and 18 females) who were diagnosed as malignant melanoma and followed up. Excision was done around 2 cm from edge of tumor regardless of the size or effected degree of the skin, and flap or full thickness skin graft was used for skin deficit that was not covered after excision. As for immuno-chemotherapy, method that prescribes 400 mg of dacarbazine (DTIC) and 3 million IU of interferone-${\alpha}$ in combination was used. Immuno-chemotherapy was operated to patients in over stage III. We used AJCC stage that was revised in 2002. Local recurrence, local metastasis and distant metastasis were investigated for these patients as well as the 5-year survival rate of each stage. Results: Most frequently 15 cases(42.8%) occurred in foot, 5 cases(14.2%) occured in ankle, 2 cases(5.7%) in leg, 2 cases(5.7%) in thigh and 5 cases(14.2%) in hand. The incidence of each stage were 8 cases(22.8%) in IA, 9 cases(25.7 %) in IB, 4 cases(11.4%) in IIA, 2 cases(5.7%) in IIB, 1 cases(2.8%) in IIIA, 2 cases(5.7%) in IIIB, 2 cases(5.7%) in IIIC and 7 cases(20.0%) in stage IV. 5-year survival rate of each stage were 94.1% in stage I, 66.8% in stage II, 40% in stage III and 14.3% in stage IV. Conclusion: 5-year survival rate of stage IV was low in malignant melanoma. In treatment of malignant melanoma, staging before operation is important as operation methods are different from each stage. We recommend wide excision which remove around 1~3 cm from margin of tumor up to each thickness.

  • PDF

Malignant Melanoma (악성 흑색종)

  • Rhee, Seung-Koo;Kang, Yong-Koo;Park, Won-Jong;Chung, Yang-Guk;Lee, Hyuk-Je
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.7 no.1
    • /
    • pp.13-19
    • /
    • 2001
  • Background : The incidence of malignant melanoma is currently increasing at a rate greater than any other cancer occuring in human. At this time, early diagnosis and surgical excision were the mainstay of treatment for patients with malignant melanoma. We reviewed the results of average 4 years of follow-up after surgical excision of total 16 cases of malignant melanoma since 1985. Materials and Methods : There were 16 patients (mean age 58.5 years, 5 men, 11 women). The site of the primary lesion was foot and toe (6), back (3), hand (2), thigh (2), shoulder (1), lower abdomen (1) and lip (1). The lymph node was involved at 9 patients. The histologic diagnosis was made with H-E, S-100 stain, and HMB-45 stain as a special stain. Results : Histologically, there were Clark's stage I for 3 patients, II in 4, III in 2, IV in 3, and stage V in 4 patients. The wide excision only greater than 2cm margin was performed for 4 patients. The wide excision and lymph node dissection were performed for 4 patients. The amputation was only performed for 3 patients, and the amputation and lymph node dissection were performed for 5 patients. After surgical excision, chemotherapy was done with Taxol for each 2 patients of stage IV and V. After long term follow-up for mean 4 years, 4 patients died related with melanoma, 1 patient was recurred, and 11 patients were cured. Conclusion : The incidence of malignant melanoma was rare in Korea, but early involvement of lymph node at initial diagnosis was found in many cases (9/16, 56%). And then, early detection and appropriated excision as well as careful dissection of adjacent lymph nodes will offer the patient the best chance for cure.

  • PDF

Analysis of Treatment Results of Malignant Melanoma (악성 흑색종의 치료결과 분석)

  • Shin, Duk-Seop;Kim, Ui-Sik
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.17 no.1
    • /
    • pp.30-35
    • /
    • 2011
  • Purpose: This study was designed to evaluate the treatment results of malignant melanoma and to analyze the factors influencing prognosis. Materials and Methods: Thirty one cases of malignant melanoma were included in this study. They were treated in our hospital surgically, medically and immunologically from January 1996 to December 2005, and were followed more than 5 years. We compared 5 year survival rate (5YSR) according to the age, gender, anatomical site, depth of tumor, TNM stage, involvement of lymph node and immuno-chemotherapy. Results: Overall 5YSR was 80.6%. 5YSR of the age group below 65 years was 89.7% and 66.7% for the age group over 65 (p=0.033). 5YSR for men was 75% and 90.9% for women. 5YSR according to the site of occurrence showed 66.7% in upper extremities, 89.5% in lower extremities, and 66.7% in other site. 5YSR was 100% for the Clark level below III and 62.5% for the level above IV (p=0.032). 5YSR was 53.8% for lymph node metastasis group and 100% for non-lymph node metastasis group (p=0.021). Conclusion: We concluded that early diagnosis and wide excision was the most important in treatment of malignant melanoma. The prognostic fractors of malignant melanoma were age, depth of tumor (Clark's stage) and metastasis of lymph node.

A Case of Unknown Primary Malignant Melanoma with Pulmonary and Endobronchial Metastasis (다발성 폐종괴 및 기관지 점막으로 전이한 원발불명의 악성 흑색종 1예)

  • Min, Young-Hoon;Kim, Sung-Wook;Chin, Hui-Jong;Lee, Tae-Yoo;Song, Hun-Ho;Lee, Keun-Seok;Lee, Jung-Ae;Park, Young-Lee;Hyun, In-Gyu
    • Tuberculosis and Respiratory Diseases
    • /
    • v.53 no.2
    • /
    • pp.196-201
    • /
    • 2002
  • Malignant melanoma is a highly malignant form of cutaneous cancer derived from melanocytes. The lesion frequently metastasizes to the lymph nodes, lung, liver and bone. However, an endobronchial metastasis and a primary malignant. melanoma of the lung are quite rare. We report a case of an unknown primary malignant melanoma with a pulmonary and endobronchial metastasis in a 34 years old male. He complained of coughing and black-colored sputum. Abnormal skin and mucosal lesions were not found during a physical examination. A chest X-ray revealed multiple nodular masses in both lung fields. A flexible bronchoscopy showed two yellowish small nodules at the entry of left lower bronchus. Vimentin, the S-100 protein, and HMB-45 stain positive melanoma cells were detected at the bronchoscopic biopsy specimen.

Ginsenoside Rg3 Induces Apoptosis in B16F10 Melanoma Cells (ginsenoside Rg3에 의한 B16F10 흑색종 세포의 세포사멸 유도)

  • Lee, Seul Gi;Kim, Byung Soo;Nam, Ju-Ock
    • Journal of Life Science
    • /
    • v.24 no.9
    • /
    • pp.1001-1005
    • /
    • 2014
  • Ginsenoside Rg3 is one of the active ingredients extracted from red ginseng, and it is an effective chemical component of the human body and well known in herbal medicine as a restorative agent. Several studies have shown that Rg3 has a potent anti-tumor effect on various cancer cell lines. However, Rg3-induced apoptosis in B16F10 melanoma cancer cells is not well understood. In the present study, we tested whether ginsenoside Rg3 could induce apoptosis in B16F10 melanoma cells. We found that Rg3 could inhibit B16F10 melanoma cell viability in a dose-dependent manner, but not normal cells, such as EA.hy.926 and NIH3T3 cells. We also found that Rg3 could induce apoptosis in B16F10 melanoma cells using tunnel-staining assay in a dose-dependent manner. Rg3 treatment induces the phosphorylation of p38 and the expression of Bax, but it inhibits the expressions of the phosphorylation of focal adhesion kinase Bcl2 and pro-caspase3. Taken together, our data suggest that Rg3 could be useful as an anti-cancer agent in B16F10 melanoma cells.

A Study on the Change of Production Performance of 5 Strains of Korean Native Chicken after Establishment of Varieties (한국재래닭 5계통의 종 조성 후 생산능력 변화 추이에 관한 연구)

  • Kim, Ki Gon;Kang, Bo Seok;Park, Byoung Ho;Choo, Hyo Jun;Kwon, Il;Choi, Eun Sik;Sohn, Sea Hwan
    • Korean Journal of Poultry Science
    • /
    • v.46 no.3
    • /
    • pp.193-204
    • /
    • 2019
  • This study aimed to investigate the changes in production performance of five strains of Korean native chickens (KNCs), which have been collected and established at the National Institute of Animal Science, Korea, since 1992. A total of 38,026 KNCs were tested and survival rate, body weight, age at first egg-laying, hen-housed egg production, and egg weight was analyzed. The mean survival rates of KNCs were $87.9{\pm}0.8%$, but no significant difference in survival rate between strains and in the annual survival rates of KNCs was observed. The average body weight of KNCs was $1,609.7{\pm}21.3g$ at 150 d. The average body weight of KNC-Black was the highest, whereas KNC-White had the lowest weight. A gradual increase in the annual weight change has been observed in almost all strains after 2004. The average age at first egg-laying was $146.9{\pm}1.1d$ in KNCs where KNC-White was the earliest and KNC-Black was the latest. The age at first egg-laying has increased after 2003, but has gradually decreased after 2008. The average hen-housed egg production at 270 d was $77.3{\pm}1.7$ in KNCs, wherein KNC-Yellowish brown was the highest and KNC-Black was the lowest. The average egg weight at 270 d was $51.2{\pm}0.3g$ in KNCs, indicating that KNC-Black was the heaviest, whereas KNC-White was the lightest. A significant increase in annual egg weight has been observed since 2008. To conclude, the appearance and feather colors of KNCs have improved uniformly, and the body weight has also improved slightly since 2002.

Malignant Melanoma Arising from the Mediastinum - A Case Report - (종격동에 발생한 악성 흑색종;1례 보고)

  • 이석열
    • Journal of Chest Surgery
    • /
    • v.25 no.8
    • /
    • pp.791-794
    • /
    • 1992
  • Authors experienced a case of malignant melanoma of the mediastinum, At the time of first visit to the hospital, the female patient, aged 48, and had chief complaints of right shoulder pain that was radiated to its forearm and right Horner`s syndrome. In chest X-ray and CT, extrapulmonary circumscribed mass in the right apicomedial aspect of mediastinum was found. She had no nevus and no melanoma on entire skin area. We excised the tumor and confirmed it as malignant melanoma by histopathology.

  • PDF

비인강 점막성 악성 흑색종 2례

  • Han Ji-Yeon;Kim Hun-Gyo;Hong Yeong-Seon;Lee Gyeong-Sik;Kim Dong-Jip;Park Yeong-Hak;Kim Min-Sik;Jo Seung-Ho;Seo Byeong-Do
    • 대한두경부종양학회:학술대회논문집
    • /
    • 1994.11a
    • /
    • pp.26.1-26.1
    • /
    • 1994
  • PDF

Evaluation of the Radioimmunotherapy Using I-131 labeled Vascular Endothelial Growth Factor Receptor2 Antibody in Melanoma Xenograft Murine Model (흑색종에서의 I-131표지 혈관내피세포성장인자 수용체2항체를 이용한 방사면역치료 평가)

  • Kim, Eun-Mi;Jeong, Hwan-Jeong;Park, Eun-Hye;Cheong, Su-Jin;Lee, Chang-Moon;Jang, Kyu-Yun;Kim, Dong-Wook;Lim, Seok-Tae;Sohn, Myung-Hee
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.42 no.4
    • /
    • pp.307-313
    • /
    • 2008
  • Purpose: Vascular endothelial growth factor (VEGF) and its receptor, fetal liver kinase 1 (Flk-1), play an important role in vascular permeability and tumor angiogenesis. The aim of this study is to evaluate the therapeutic efficacy of $^{131}I$ labeled anti-Flk-1 monoclonal antibody (DC101) on the growth of melanoma tumor, which is known to be very aggressive in vivo. Materials and Methods: Balb/c nude mice were injected subcutaneously with melanoma cells in the right flank. Tumors were allowed to grow up to $200-250\;mm^3$ in volume. Gamma camera imaging and biodistribution studies were performed to identify an uptake of $^{131}I$-DC101 in various organs. Mice with tumor were randomly divided into five groups (10 mice per group) and injected intravenously; control PBS (group 1), $^{131}I$-DC101 $50\;{\mu}g/mouse$ (group 2), non-labeled DC101 $50\;{\mu}g/mouse$ (group 3), $^{131}I$-DC101 $30\;{\mu}g/mouse$ (group 4) and $15\;{\mu}g/mouse$ (group 5) every 3 or 4 days for 20 days. Tumor volume was measured with caliper twice a week. Results: In gamma camera images, the uptake of $^{131}I$-DC101 into tumor and thyroid was increased with time. Biodistribution results showed that the radioactivity of blood and other major organ was gradually decreased with time whereas tumor uptake was increased up to 48 hr and then decreased. After 4th injection of $^{131}I$-DC101, tumor volume of group 2 and 4 was significantly smaller than that group 1. After 5th injection, the tumor volume of group 5 also significantly reduced. Conclusion: These results indicated that delivery of $^{131}I$ to tumor using FlK-1 antibody, DC101, effectively blocks tumor growth in aggressive melanoma xenograft model.